觀點光大證券

Tough justice for Everbright is best medicine for China

What if JPMorgan’s multibillion-dollar “London whale” trading losses had led regulators to ban Jamie Dimon, chief executive, from markets for life and forbidden the bank from ever investing again in credit derivatives?

Such a draconian scenario might sound far-fetched in the US or Europe. But this is exactly the scale of the punishment that has been meted out in China against Everbright Securities, after the brokerage committed a massive trading error two weeks ago and tried to conceal it.

The Everbright scandal has received scant attention outside China – which is perhaps understandable given the closed nature of the country’s markets: few foreign institutions or investors have been directly affected by it. Yet it is an extraordinary story that merits a closer look, because it exposes the ugly underbelly of China’s brokerage industry and shows that regulators are serious about whipping it into shape.

您已閱讀20%(912字),剩餘80%(3700字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×